The Presence of Non-organ-specific Autoantibodies in Chronic Hepatitis C Treatment-naive Patients

Background: In the patients with hepatitis C virus (HCV) various immune mediated phenomena are described, and non organ specific autoantibodies (NOSAs) in particular are common. The aim of the present study was to investigate the NOSAs prevalence in chronic hepatitis C treatment naive patients. Patients and Methods: Sera of 76 consecutive HCV treatment naive patients were considered to be eligible for this study for evaluation of Antinuclear, antismooth muscle, antimitochondrial, antineutrophil cytoplasmatic and antiliver kidney microsomal antibodies. Criteria of eligibility were serum antiHCV antibody and HCV RNA positivity, chronic inflammation revealed by histological analysis of the liver, genotyping, treatment naive patients, and no have the diagnosis of probable or definite autoimmune hepatitis. Results: Mean chronological age for the 76 patients (44 females and 32 males) was 51.3 years (range: 20 to 67 years). Nineteen patients (25.0%) infected with HCV had detectable levels of NOSAs at before combined antiviral treatment. SMA was present in 16 (21.0%) of 76 patients, ANA in 2 patients (2.6%), and pANCA (perinuclear ANCA) in 1 patients (1.3%). No patient had specimens reactive to AMA, LMK, or cANCA (cytoplasmic ANCA). Conclusions: In this study, we show the NOSAs positivity in chronic hepatitis c treatment naive patients. Assigned to high prevalence of SMA positivity is associated with high METAVIR score, and HCV genotype 1 and 1b, may reflect a release of intracellular antigens at the time of hepatocellular injury triggering immune responses in the form of autoantibody production or a direct infection of immunocytes by the HCV. Keywords: hepatitis C, treatment naive, non organ specific antibodies, chronic liver disease

Download Full-text

PIN22 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C TREATMENT-NAIVE PATIENTS IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.894 ◽

2019 ◽

Vol 22 ◽

pp. S197-S198

Author(s):

X. Wei ◽

Y. Feng ◽

L. Yang

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Direct Acting Antivirals ◽

Hepatitis C Treatment ◽

Treatment Naïve ◽

Direct Acting

Download Full-text

EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY

10.36106/5009819 ◽

2021 ◽

pp. 27-30

Author(s):

Manisha Thakur ◽

Anurag Chauhan ◽

Prashant Jambunathan ◽

Shikha Awasthi ◽

Thilagavathi K ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Sustained Viral Response ◽

Hcv Rna ◽

Hepatitis C Infection ◽

Genotype 3 ◽

Treatment Naïve

AIMS AND OBJECTIVES: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. We studied 67 treatment naive METHODS: patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram. Our results show that 70.5% (p<0.05) achieved a rapid vi RESULTS: rological response, 88.5% (p<0.05) achieved an end of treatment response and, similarly, an impressive 88.05% (p<0.05) showed a sustained virological response at the end of 12 weeks. One patient who developed a psoriasiform rash discontinued the medication and was excluded from the analysis, as duration of treatment had not been completed. No major dose related adverse events were reported. Sofosbuvir and Daclatasvir is an acceptable, well tolerated regimen for treatment naive, CONCLUSIONS: compensated patients with genotype 3 infection. Based on our observations and data, we recommend this as the rst line DAA for patient with compensated genotype 3 infection until medications with higher SVR 12 are available in the Indian market.

Download Full-text

509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study

Journal of Hepatology ◽

10.1016/s0168-8278(04)90509-0 ◽

2004 ◽

Vol 40 ◽

pp. 150 ◽

Cited By ~ 6

Author(s):

J.M. Sanchez-Tapias ◽

M. Diago ◽

P. Escartin ◽

J. Enriquez ◽

R. Moreno ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Prolonged Treatment ◽

Hcv Rna ◽

Treatment Naïve ◽

Peginterferon Alfa

Download Full-text

PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

Mediterranean Journal of Hematology and Infectious Diseases ◽

10.4084/mjhid.2017.003 ◽

2016 ◽

Vol 9 (1) ◽

pp. e2017003 ◽

Cited By ~ 3

Author(s):

Kalliopi Zachou ◽

Pinelopi Arvaniti ◽

Nikolaos K. Gatselis ◽

Kalliopi Azariadis ◽

Georgia Papadamou ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Treatment ◽

Response To Treatment ◽

Hcv Rna ◽

Severe Liver Disease ◽

Hcv Screening ◽

The Stability ◽

Direct Acting

Background & objectives: In the past, patients with haemoglobinopathies were at high risk for acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients the coexistence of haemochromatosis and chronic hepatitis C (CHC) often leads to more severe liver disease. We assessed the HCV prevalence, clinical characteristics and outcome in this setting with particular attention to the response to treatment including therapies with the new direct acting antivirals (DAAs).Methods: The medical records of 81 consecutive patients followed the last 15 years were reviewed retrospectively.Results: 43/81 (53%) patients were anti-HCV positive including 31/43 (72.1%) with CHC (HCV-RNA positive; age 25±7 years; 45.2% with genotype 1b; 19.4% cirrhotics; baseline ferritin 887 ng/ml; range: 81-10.820). Thirty patients received IFN-based therapy with or without ribavirin with sustained virological response (SVR) in 14/30 (46.7%). Eleven patients (9 non-responders to IFN-based therapies, 1 relapser and 1 naïve) received treatment with DAAs (SVR: 100%). 3/11 patients increased their transfusion needs while 1/11 reported mild arthralgias. No drug-drug interactions between DAAs and chelation agents were observed as attested by the stability of ferritin levels during treatment. Conclusions: More than 1/3 of patients with haemoglobinopathies suffered from CHC. Response rates to antiviral treatment seem to be similar to other patients with CHC, while treatment with DAAs was very effective and safe even in difficult to treat patients (most null responders with severe fibrosis) suggesting that this group of HCV patients should no longer be regarded as a difficult to treat.

Download Full-text